2019
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Age-Related Macular Degeneration Preferred Practice Pattern®. Ophthalmology 2019, 127: p1-p65. PMID: 31757502, DOI: 10.1016/j.ophtha.2019.09.024.Peer-Reviewed Original ResearchAcademies and InstitutesAgedAngiogenesis InhibitorsColoring AgentsFemaleFluorescein AngiographyHumansIndocyanine GreenIntravitreal InjectionsLaser CoagulationMacular DegenerationMaleOphthalmologyPractice Patterns, Physicians'Quality of Health CareTomography, Optical CoherenceUnited StatesVascular Endothelial Growth Factor ARetinal Vein Occlusions Preferred Practice Pattern®
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Retinal Vein Occlusions Preferred Practice Pattern®. Ophthalmology 2019, 127: p288-p320. PMID: 31757503, DOI: 10.1016/j.ophtha.2019.09.029.Peer-Reviewed Original Research
2017
Age‐related macular degeneration: using morphological predictors to modify current treatment protocols
Ashraf M, Souka A, Adelman RA. Age‐related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmologica 2017, 96: 120-133. PMID: 29130626, DOI: 10.1111/aos.13565.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAngiogenesis InhibitorsClinical ProtocolsDatabases, FactualHumansPatient-Centered CarePrognosisTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityWet Macular DegenerationConceptsAge-related macular degenerationPigment epithelial detachmentChoroidal neovascular membranePosterior vitreous detachmentNeovascular age-related macular degenerationRetinal angiomatous proliferationSubretinal fluidIntraretinal cystsVitreomacular adhesionVisual outcomeVisual acuityPrognostic indicatorMacular degenerationAnti-vascular endothelial growth factorLarger choroidal neovascular membranesWet age-related macular degenerationOlder ageCNV sizeFinal visual outcomeGood visual outcomeAnti-VEGF therapyPoor prognostic indicatorCurrent treatment protocolsEndothelial growth factorInjection frequency
2016
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients
Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology 2016, 124: 352-358. PMID: 27890437, DOI: 10.1016/j.ophtha.2016.10.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabCohort StudiesDatabases, FactualDiabetic RetinopathyDrug UtilizationFemaleHumansInsurance, HealthIntravitreal InjectionsMacular DegenerationMaleMedicare Part CMiddle AgedOphthalmologyPrivate SectorRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionRetrospective StudiesUnited StatesVascular Endothelial Growth Factor AYoung AdultConceptsAge-related macular degenerationDiabetic retinal diseaseAnti-VEGF injectionsIntravitreal anti-VEGF injectionsRetinal vein occlusionAdministrative claims dataRetinal diseasesOphthalmic diseasesVein occlusionClaims dataUse of bevacizumabCurrent Procedural Terminology codesPatients 18 yearsRetrospective cohort studyMedicare Advantage patientsOptumLabs Data WarehouseDrug Administration approvalProcedural Terminology codesGrowth factor useRanibizumab useBevacizumab useAvailable medicationsCohort studyMedication useCommon medicationsAflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 2016, 30: 1531-1541. PMID: 27564719, PMCID: PMC5177746, DOI: 10.1038/eye.2016.174.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsClinical Trials as TopicDiabetic RetinopathyDrug Administration ScheduleHumansMacular EdemaReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AConceptsDiabetic macular edemaMacular edemaLarge phase 3 trialsBetter baseline VAEfficacy of afliberceptRole of afliberceptSecondary therapeutic optionsPhase 3 trialProtocol TBaseline VABimonthly regimenNata protocolAnatomic outcomesTherapeutic optionsPoor visionTreatment strategiesPrimary drugAfliberceptDifferent dosesDoseRanibizumabRegimenEdemaPatientsRecent dataPredicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal Of Ophthalmology 2016, 100: 1596. PMID: 27231313, DOI: 10.1136/bjophthalmol-2016-308388.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsBevacizumabDiabetic RetinopathyFluorescein AngiographyFundus OculiHumansMacula LuteaMacular EdemaPrognosisRanibizumabTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityConceptsDiabetic macular edemaOptical coherence tomographyMacular edemaAnti-vascular endothelial growth factor therapyIntravitreal anti-vascular endothelial growth factorAnti-vascular endothelial growth factorEndothelial growth factor therapyFluorescein angiography findingsAnti-VEGF therapyAnti-VEGF agentsGrowth factor therapyCourse of treatmentCommon prognostic indicatorsEndothelial growth factorFactor therapyMost patientsVisual outcomeAngiography findingsChoroidal thicknessLarge RCTsTreatment regimenOCT parametersVisual acuityPrognostic indicatorDifferent RCTs
2015
Strategy for the Management of Macular Edema in Retinal Vein Occlusion: The European VitreoRetinal Society Macular Edema Study
Adelman RA, Parnes AJ, Bopp S, Othman I, Ducournau D. Strategy for the Management of Macular Edema in Retinal Vein Occlusion: The European VitreoRetinal Society Macular Edema Study. BioMed Research International 2015, 2015: 870987. PMID: 25705695, PMCID: PMC4325227, DOI: 10.1155/2015/870987.Peer-Reviewed Original ResearchConceptsRetinal vein occlusionCentral retinal vein occlusionBranch retinal vein occlusionVein occlusionMacular edemaVisual acuityIntravitreal antivascular endothelial growth factor injectionsAntivascular endothelial growth factor injectionsCases of RVOEndothelial growth factor injectionsGrowth factor injectionsChoice of treatmentMulticenter collaborative studyEdema studyFactor injectionsNonsurgical treatmentNumber of treatmentsVEGF injectionPlana vitrectomyRVO casesILM peelingRetina specialistsVisual gainDiagnostic findingsVisual improvement
2014
Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients
Hall LB, Zebardast N, Huang JJ, Adelman RA. Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients. Journal Of Ocular Pharmacology And Therapeutics 2014, 30: 346-352. PMID: 24552305, DOI: 10.1089/jop.2013.0188.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAntibodies, Monoclonal, HumanizedBevacizumabFemaleHumansIntravitreal InjectionsMacular DegenerationMaleRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinaRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityConceptsAge-related macular degenerationCentral macular thicknessAflibercept injectionsInitial visitMacular degenerationAnti-vascular endothelial growth factor treatmentNeovascular age-related macular degenerationEndothelial growth factor treatmentCentral macular edemaIntraocular pressure increaseSubset of patientsMain outcome measuresOptical coherence tomographyGrowth factor treatmentMacular thicknessNeovascular AgeOcular hypertensionSubmacular fluidVisual outcomeMacular edemaRetrospective studyVisual acuityOutcome measuresStudy populationPatients
2013
Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents
Abedi G, Adelman RA, Salim S. Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents. Seminars In Ophthalmology 2013, 28: 126-130. PMID: 23631423, DOI: 10.3109/08820538.2013.771195.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabHumansIncidenceIntraocular PressureIntravitreal InjectionsOcular HypertensionRanibizumabVascular Endothelial Growth Factor AConceptsPersistent ocular hypertensionIntraocular pressureOcular hypertensionIntravitreal antivascular endothelial growth factorAntivascular endothelial growth factor agentsChronic intraocular pressure elevationEndothelial growth factor agentsIntravitreal anti-VEGF injectionsAntivascular endothelial growth factorAnti-VEGF injectionsGrowth factor agentsIntraocular pressure elevationElevated intraocular pressureElectronic literature searchEndothelial growth factorKey search termsFactor agentsPrompt diagnosisVEGF injectionAcute elevationIntravitreal injectionIOP elevationPersistent elevationPressure elevationGlaucomatous eyes
2011
The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab
Lee ST, Adelman RA. The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab. Journal Of Ocular Pharmacology And Therapeutics 2011, 27: 611-614. PMID: 21810026, DOI: 10.1089/jop.2011.0045.Peer-Reviewed Original ResearchConceptsRecurrent central serous chorioretinopathyMean central macular thicknessCentral macular thicknessCentral serous chorioretinopathyPreinjection visual acuityVisual acuityOptical coherence tomographyIntravitreal bevacizumabSerous chorioretinopathyTreatment optionsLow-risk treatment optionYale Eye CenterIntravitreal bevacizumab injectionRetrospective case seriesEffective treatment optionLong-term efficacySub-retinal fluidNumber of injectionsFluorescein angiography imagingBevacizumab injectionRecurrent diseaseMacular thicknessMonth 3Month 6Case series
2010
Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections
Adelman RA, Zheng Q, Mayer HR. Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections. Journal Of Ocular Pharmacology And Therapeutics 2010, 26: 105-110. PMID: 20187807, DOI: 10.1089/jop.2009.0076.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInjections, IntraocularIntraocular PressureMacular DegenerationMaleOcular HypertensionRanibizumabRetrospective StudiesTime FactorsVascular Endothelial Growth Factor AVitreous BodyConceptsAge-related macular degenerationPersistent ocular hypertensionOcular hypertensionIntraocular pressureIntravitreal bevacizumabRanibizumab injectionsIntravitreal injectionPrevious diagnosisGlaucoma/ocular hypertensionIntravitreal anti-VEGF injectionsAnti-VEGF injectionsIntravitreal bevacizumab injectionPostinjection intraocular pressurePreinjection intraocular pressureMultiple intravitreal injectionsTertiary referral centerRetrospective case seriesElevated intraocular pressureBevacizumab injectionIntravitreal ranibizumabReferral centerCase seriesVEGF injectionIOP increaseYAG capsulotomy
2009
Minimal Effects of VEGF and Anti-VEGF Drugs on the Permeability or Selectivity of RPE Tight Junctions
Peng S, Adelman RA, Rizzolo LJ. Minimal Effects of VEGF and Anti-VEGF Drugs on the Permeability or Selectivity of RPE Tight Junctions. Investigative Ophthalmology & Visual Science 2009, 51: 3216-3225. PMID: 20042644, PMCID: PMC2891474, DOI: 10.1167/iovs.09-4162.Peer-Reviewed Original ResearchAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabBlood-Retinal BarrierCapillary PermeabilityCells, CulturedClaudinsElectric ImpedanceEnzyme-Linked Immunosorbent AssayFluorescent Antibody Technique, IndirectGene ExpressionHumansImmunoblottingPolyethylene GlycolsPotassiumRanibizumabRetinal Pigment EpitheliumReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSodiumTight JunctionsVascular Endothelial Growth Factor AASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS
SETH RK, SALIM S, SHIELDS MB, ADELMAN RA. ASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS. Retina 2009, 29: 956-959. PMID: 19584654, DOI: 10.1097/iae.0b013e3181a91dfd.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideDrug Therapy, CombinationEyeFollow-Up StudiesFundus OculiHumansInjectionsIntraocular PressureOptic DiskOptic NerveRanibizumabRegional Blood FlowRetrospective StudiesSingle-Blind MethodVascular Endothelial Growth Factor AVitreous BodyConceptsMultiple intravitreal injectionsAnti-VEGF agentsIntraocular pressure riseIntraocular pressure fluctuationIntravitreal injectionMean changeControl groupTransient intraocular pressure riseSignificant differencesDisc ratio changesOptic nerve cupHistory of glaucomaAdditional prospective studiesGrowth factor effectsFellow eyesGlaucoma specialistsOptic nerveProspective studyOptic disc imagesFundus photographsTriamcinolone acetonideInclusion criteriaDisc ratioVertical cupPatients
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator